Inventor · disambiguated record
John Kane
Also filed as: KANE JOHN · KANE JOHN L · KANE JOHN L JR · KANE JR JOHN L
22 granted patents·7 pending applications·140 citations·filing 2001–2025
95Inventor score
Top patents by PatentIndex Score
29 records- 0196US11878024B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2022·Granted Jan 23, 2024·3 cites·6 claims
- 0296US11406644B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2020·Granted Aug 9, 2022·5 cites·21 claims
- 0394US12318392B2Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2023·Granted Jun 3, 2025·1 cites·27 claims
- 0494US9174986B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2015·Granted Nov 3, 2015·13 cites·1 claims
- 0593US9067914B1Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2014·Granted Jun 30, 2015·15 cites·1 claims
- 0692US10166239B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2017·Granted Jan 1, 2019·9 cites·33 claims
- 0792US9611265B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2015·Granted Apr 4, 2017·11 cites·10 claims
- 0890US8304447B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsSIEGEL CRAIG·Filed 2008·Granted Nov 6, 2012·18 cites·20 claims
- 0988US8309593B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsSIEGEL CRAIG·Filed 2009·Granted Nov 13, 2012·15 cites·15 claims
- 1087US8940776B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsSIEGEL CRAIG·Filed 2012·Granted Jan 27, 2015·11 cites·19 claims
- 1185US2025288595A1Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2025·Application pending·0 cites
- 1284US11274108B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2016·Granted Mar 15, 2022·2 cites·15 claims
- 1382US9272996B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsSIEGEL CRAIG·Filed 2012·Granted Mar 1, 2016·6 cites·16 claims
- 1480US6969728B2Modulators of TNF-α signalingGENZYME CORP·Filed 2001·Granted Nov 29, 2005·12 cites·64 claims
- 1579US12503477B2Colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2024·Granted Dec 23, 2025·0 cites·6 claims
- 1679US9745294B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2014·Granted Aug 29, 2017·3 cites·24 claims
- 1778US7034031B2Modulators of TNF-α signalingGENZYME CORP·Filed 2004·Granted Apr 25, 2006·9 cites·19 claims
- 1876US8921547B2Modulators of TNF-α signalingGENZYME CORP·Filed 2013·Granted Dec 30, 2014·2 cites·16 claims
- 1975US11530216B2Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitorsGENZYME CORP·Filed 2022·Granted Dec 20, 2022·1 cites·28 claims
- 2072US9744153B22-acylaminopropoanol-type glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2016·Granted Aug 29, 2017·1 cites·14 claims
- 2171US8518999B2Modulators of TNF-αsignalingSNEDDON SCOTT F·Filed 2005·Granted Aug 27, 2013·2 cites·16 claims
- 2269US2022396588A1Colony stimulating factor-1 receptor (csf-1r) inhibitorsGENZYME CORP·Filed 2022·Application pending·0 cites
- 2368US2019183903A1Tropomyosin-related kinase (trk) inhibitorsGENZYME CORP·Filed 2018·Application pending·0 cites
- 2464US9579325B2Modulators of TNF-α signalingGENZYME CORP·Filed 2014·Granted Feb 28, 2017·0 cites·1 claims
- 2564US7541466B2Tetrahydroisoquinoline derivatives for treating protein trafficking diseasesGENZYME CORP·Filed 2004·Granted Jun 2, 2009·1 cites·33 claims
- 2657US2018093981A12-Acylaminopropoanol-Type Glucosylceramide Synthase InhibitorsGENZYME CORP·Filed 2017·Application pending·0 cites
- 2742US2007254894A1Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferationKANE JOHN L JR·Filed 2007·Application pending·0 cites
- 2842US2011275673A1Inhibitors of sphingosine kinase 1XIANG YIBIN·Filed 2009·Application pending·0 cites
- 2936US2017281641A1CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORSGENZYME CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Kane files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →